Press Release

Accuro Biologics client AC Immune announces significant clinical milestones in Alzheimer's disease drug development

ABERDEEN, UK -- December 2008 -- Accuro Biologics client AC Immune announces significant clinical development milestones in Alzeimer's disease drug development. In a statement issued December 4th, the company highlighted that Genentech Inc which holds an exclusive licence to develop the AC Immune anti-Abeta antibody, was granted fast track designation by the US Food and Drug Administration for the clinical development program in mild to moderate Alzheimer's disease.

For more information see: AC Immune Press Release (PDF, 120KB)

Return to Press Releases